TCB-2 is a hallucinogen discovered in 2006 by Thomas McLean working in the lab of David Nichols at Purdue University. [1] It is a conformationally-restricted derivative of the phenethylamine 2C-B, also a hallucinogen, and acts as a potent agonist for the 5-HT 2A and 5-HT 2C receptors with a K i of 0.26 nM at the human 5-HT 2A receptor.

Oct 13, 2009 · Here we provide the first behavioral and neurophysiological profile of TCB-2 in C57BL/6J mice, with direct comparisons to the 5-HT2A/2C agonist (±)-2,5-dimethoxy-4-iodophenyl-2-aminopropane (DOI), in addition to determinations of 5-HT2A mediation via pretreatment with the selective 5-HT2A antagonist MDL 11,939.

In this study, we explored the potential of serotonin 2A receptor (5-HT 2A R) agonism to reduce alcohol consumption in male wildtype C57Bl/6J mice and to ameliorate alcohol-induced inhibitory plasticity in the midbrain.

Feb 2, 2023 · TCB-2, a 5-hydroxytryptamine 2A receptor agonist, disrupts prepulse inhibition in the ventral pallidum and nucleus accumbens Behav Brain Res . 2023 Feb 2:437:114127. doi: 10.1016/j.bbr.2022.114127.

Nov 1, 2018 · TCB-2 is a potent 5-HT 2A R ligand with unknown selectivity toward other receptors. The hallucinogenic property of TCB-2 is unknown. TCB-2 behaves as other hallucinogenic drugs on cortical gamma oscillation. TCB-2 preferentially stimulates PLC over PLA2 in contrast to numerous hallucinogenic drugs.

Feb 2, 2023 · TCB-2 (10.0 μg/1.0 μl/side), M100907 (5.0 μg/1.0 μl/side) or vehicle (1.0 μl/side) were locally infused into the right lateral ventricular and target brain regions at a rate of 0.5 μl/min with micro syringe pump (GenieTouch™ syringe pump, Kent Scientific Corporation, USA).

Mar 2, 2022 · In this study, we explored the potential of serotonin 2A receptor (5-HT 2A R) agonism to reduce alcohol consumption in male wild-type C57Bl/6J mice and to ameliorate alcohol-induced inhibitory plasticity in the midbrain.

TCB-2 is a novel psychedelic substance that enhances the consolidation of object memory and acts as an activator of the 5-hydroxytryptamine (5-HT, serotonin) type 2A receptor. It has been shown to increase cell membrane expression of KCC2, restore GABAergic inhibition, and improve functional outcomes in a rat spinal cord injury model.

OBJECTIVES: Here we provide the first behavioral and neurophysiological profile of TCB-2 in C57BL/6J mice, with direct comparisons to the 5-HT(2A/2C) agonist (+/-)-2,5-dimethoxy-4-iodophenyl-2-aminopropane (DOI), in addition to determinations of 5-HT(2A) mediation via pretreatment with the selective 5-HT(2A) antagonist MDL 11,939.